

1/25




Fig. 1a




Fig. 1b

3/25

TO6T60" T2405600




Fig. 1c

$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & i \\ 0 & 1 \end{pmatrix}$ $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & -i \\ 0 & 1 \end{pmatrix}$ $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}$ $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}$ $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}$




Fig. 1d

5/25

706760-7240960




Fig. 1e

6/25

095604-100000




Fig. 1f

7/25




Fig. 1g

8/25




Fig. 2a

9/25




Fig. 2b

10/25




Fig. 3

11/25




Fig. 4a

12/25




Fig. 4b





Fig. 4c




Fig. 5a

15/25



Pravastatin Sodium




Fluvastatin


Fig. 5b

09950471.001901

16/25



Mevastatin



Simvastatin

Fig. 5c

FIG. 5c

Ragi cells

IFN- γ /Simva
L-Mevalonate

IFN- γ /Simva

IFN- γ /Atorva

IFN- γ /Lova

IFN- γ /Prava

IFN- γ

Control




Fig. 6




Fig. 7




Fig. 8





Fig. 9a

Statin treatment



+



CD40L staining

Fig. 9b





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx




Fig. 10

Group	Number of Subjects (n)
Control	7.8
Low dose	4.5*
High dose	3.0*

Treatment	Eggs per female (approx.)	Significance
Control	10.2	
100 mg/kg	6.5	*
200 mg/kg	4.5	*

Fig. 11

	³ H] Thymidine incorporation [cpm]	IFN- γ production [pg/ml]
Control	13,830 (\pm 7,078)	60,112 (\pm 13,532)
Low dose	6,508 (\pm 6,499) *	36,368 (\pm 8,005) *
High dose	5,221 (\pm 7,632) *	29,805 (\pm 8,114) *

Fig. 12